Embryonic Ectoderm Development (EED) as a Novel Target for Cancer Treatment

Nicholas Cook, Jianping Chen, Jia Zhou, Daqing Wu

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

The polycomb repressive complex 2 (PRC2) can methylate at lysine 27 of histone H3 at the trimethylation level (H3K27me3). This leads to gene silencing and is known to be dysregulated in many cancers. PRC2 is made up of three core subunits: EZH2, SUZ12, and EED. EED is essential for the regulation of PRC2 function by binding to H3K27me3. Targeting the allosteric site within EED offers new strategies to disrupt the PRC2 activity. In this minireview, we summarize some of the recent developments in small molecules that target EED and its interaction with other core proteins in the PRC2 complex.

Original languageEnglish (US)
Pages (from-to)2771-2777
Number of pages7
JournalCurrent topics in medicinal chemistry
Volume21
Issue number31
DOIs
StatePublished - Dec 2021

Keywords

  • Cancer
  • Degrader
  • EED
  • EZH2
  • Inhibitor
  • PRC2

ASJC Scopus subject areas

  • Drug Discovery

Fingerprint

Dive into the research topics of 'Embryonic Ectoderm Development (EED) as a Novel Target for Cancer Treatment'. Together they form a unique fingerprint.

Cite this